A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell Lymphoma

•Autologous and allogeneic hematopoietic cell transplantation are both effective consolidative strategies in patients with Hepatosplenic T Cell Lymphoma.•Median overall survival and progression free survival for the entire cohort were 78.5 months (95% CI: 25-NR) and 54 months (95% CI: 18 to 75), respectively.•No significant differences in OS or PFS we seen when comparing autologous and allogeneic HCT groups.•Pts with less than CR at time of transplant had better median overall survival with allogeneic hematopoietic cell transplantation compared to autologous hematopoietic cell transplantation (65 mo versus 7 mo, P< .001).